Clinical Trials
12 trialsNCT07624487 2026-06-05
Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma
Taipei Medical University Hospital
Phase 2 Not yet recruiting
NCT07630246 2026-06-05
PAIR-LUNG
Universidade Nova de Lisboa
Not yet recruiting
NCT05797168 2026-06-03
FONTANA
AstraZeneca
Phase 1/2 Recruiting
NCT05703516 2026-06-01
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Novartis
Recruiting
NCT04248829 2026-05-28
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Yuhan Corporation
Phase 3 Completed
NCT05764954 2026-05-28
A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT06843629 2026-05-28
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Recruiting
NCT05198830 2026-05-27
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT00334815 2026-05-26
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01386385 2026-05-26
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02186847 2026-05-22
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NRG Oncology
Phase 2 Completed
NCT04929041 2026-05-13
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
National Cancer Institute (NCI)
Phase 2/3 Suspended